Belvedere Trading
FLNA

Belvedere Trading’s Filana Therapeutics FLNA Stock Holding History

Belvedere Trading’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,500
Closed -$27.1K – 948
2024
Q4 		$27.1K Sell
11,500
-20,200
-64% -$355K ﹤0.01% 664
2024
Q3 		$933K Buy
31,700
+3,800
+14% +$87.5K ﹤0.01% 121
2024
Q2 		$345K Sell
27,900
-600
-2% -$12.6K ﹤0.01% 249
2024
Q1 		$578K Buy
28,500
+25,900
+996% +$597K ﹤0.01% 141
2023
Q4 		$58.5K Sell
2,600
-4,600
-64% -$97.2K ﹤0.01% 549
2023
Q3 		$120K Sell
7,200
-10,300
-59% -$204K ﹤0.01% 303
2023
Q2 		$429K Buy
17,500
+2,900
+20% +$69.8K ﹤0.01% 164
2023
Q1 		$352K Sell
14,600
-41,300
-74% -$1.14M ﹤0.01% 204
2022
Q4 		$1.65M Buy
55,900
+45,900
+459% +$1.65M ﹤0.01% 41
2022
Q3 		$343K Buy
+10,000
New +$270K 0.01% 96

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Belvedere Trading's FLNA Position: Q3 2024 in Review

Belvedere Trading sold out of Filana Therapeutics (FLNA) in Q3 2024, closing a stake of 7,855 shares — an estimated $181K sold.

Belvedere Trading first reported a position in FLNA in Q2 2021 and held it in 7 quarters. The position peaked at $1.19M in Q2 2021. 161 funds tracked by Wall St. Rank hold FLNA as of Q3 2024.

  • Belvedere Trading reported no remaining Filana Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Belvedere Trading sold 7,855 Filana Therapeutics shares in Q3 2024, an estimated $181K.
  • Belvedere Trading first reported a position in Filana Therapeutics in Q2 2021 and held it in 7 quarters.
  • Belvedere Trading's Filana Therapeutics position peaked at $1.19M in Q2 2021.
  • 161 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2024.

Based on Belvedere Trading's 13F filing for Q3 2024, filed 30 Oct 2024.